InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,596.40
(
1.02%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.48
(
0.42%
)
Bitcoin
63,513.70
(
-0.76%
)
Post# of 251732
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: oc631 post# 181313

Tuesday, 08/19/2014 12:08:40 PM

Tuesday, August 19, 2014 12:08:40 PM

Post# of 251732
>> The idea of raising the price of Sovaldi/GS-5816 FDC, to defend against "me-too" Sovaldi-based competitors, would be a self-defeating strategy for GILD and play into ABBV's hand within the oversized GT1 U.S. market.

Who said raising price of Sofosbuvir/GS5816 FDC? We were talking about raising the price of standing alone Sovaldi! Why would that affect GT1 from GILD point of view? Patients will be either on Sofosbuvir/ledipasvir or Sofosbuvir/GS5816.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up